Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Leuprorelin oral - Enteris BioPharma

Drug Profile

Leuprorelin oral - Enteris BioPharma

Alternative Names: Leuprolide acetate oral - Enteris BioPharma; Ovarest

Latest Information Update: 28 Feb 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Unigene Laboratories
  • Developer Enteris BioPharma; Unigene Laboratories
  • Class Antineoplastics; Gonadotropins; Infertility therapies; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Endometriosis
  • Discontinued Precocious puberty; Prostate cancer; Uterine leiomyoma

Most Recent Events

  • 28 Feb 2019 No recent reports of development identified for phase-I development in Endometriosis in USA (PO, Tablet)
  • 26 Jun 2018 Pharmacodynamics and Pharmacokinetics data from a phase IIa trial in Endometriosis released by Enteris BioPharma
  • 18 Jun 2018 Enteris BioPharma completes a phase II trial for Endometriosis (In healthy volunteers) in Canada (PO) (NCT02807363)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top